Drilldown: Medicines

Other values:

Search

None (15) · Anafranil (1) · Aurorix (1) · Betapace (1) · Brevibloc (1) · Bystolic (1) · Corgard (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zebeta (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (3) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (35) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1)

None (35) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25 mg (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 5 mg daily (1)

None (35) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 5, 10 mg tabs (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (35) · 20 mg/d (1) · 200 mg/d (1) · 40 mg/d (1) · 400 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1)

None (34) · IV (2) · Oral (6)

None (34) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (34) · 24 h (2) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · Chronic daily dosing (1) · Long (1)

None (34) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (34) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~25% (extensive hepatic first-pass) (1) · ~50% (1) · ~50% (highly variable) (1) · ~90% (low first-pass) (1)

None (34) · Category C (5) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (34) · Rx-only (1) · Rx-only in US (5)